Original language | English |
---|---|
Pages (from-to) | 105-107 |
Number of pages | 3 |
Journal | Schizophrenia Research |
Volume | 211 |
DOIs | |
Publication status | Published - 2019 Sep |
Keywords
- Adherence
- Antipsychotics
- Long-acting injectable antipsychotics
- Perception
- Schizophrenia
ASJC Scopus subject areas
- Psychiatry and Mental health
- Biological Psychiatry
Access to Document
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Psychiatrists' perceptions of medication adherence among patients with schizophrenia : An international survey. / Kurokawa, Shunya; Kishimoto, Taishiro; Su, Kuan Pin; Chang, Jane Pei Chen; Chang, Hui Chih; Yu, Xin; Rodrigues-Silva, Nuno; Nielsen, Jimmi; Unadkat, Anish; Castle, David; Haddad, Peter M.; Rocha, Deyvis; Gadelha, Ary; Kaliora, Styliani; Petrides, Georgios; Agid, Ofer; Tazawa, Yuki; Takamiya, Akihiro; Horigome, Toshiro; Kane, John M.
In: Schizophrenia Research, Vol. 211, 09.2019, p. 105-107.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Psychiatrists' perceptions of medication adherence among patients with schizophrenia
T2 - An international survey
AU - Kurokawa, Shunya
AU - Kishimoto, Taishiro
AU - Su, Kuan Pin
AU - Chang, Jane Pei Chen
AU - Chang, Hui Chih
AU - Yu, Xin
AU - Rodrigues-Silva, Nuno
AU - Nielsen, Jimmi
AU - Unadkat, Anish
AU - Castle, David
AU - Haddad, Peter M.
AU - Rocha, Deyvis
AU - Gadelha, Ary
AU - Kaliora, Styliani
AU - Petrides, Georgios
AU - Agid, Ofer
AU - Tazawa, Yuki
AU - Takamiya, Akihiro
AU - Horigome, Toshiro
AU - Kane, John M.
N1 - Funding Information: Dr. Kishimoto has received consultant fees from Otsuka, Pfizer, and Dainippon Sumitomo, and speaker's honoraria from Banyu, Eli Lilly, Dainippon Sumitomo, Janssen, Novartis, Otsuka, and Pfizer. He has received grant support from the Byoutaitaishakenkyukai Fellowship (Fellowship of Astellas Foundation of Research on Metabolic Disorders) and Eli Lilly Fellowship for Clinical Psychopharmacology. Funding Information: Drs. J. Chang, H. Chang, and Su are supported by the following grants: MOST 106-2314-B-039-027-MY3 , 106-2314-B-038-049 , 106-2314-B-039-031 , 106-2314-B-039-035 , and 105-2918-I-039-001 from the Ministry of Science and Technology, Taiwan ; NHRI-EX106-10528NI from the National Health Research Institutes , Taiwan; and CMU106-S-33 , CRS-106-063 , DMR-107-202 , DMR-107-204 , DMR-107-091 , DRM-107-097 , DRM-108-091 , CRS-108-048 and the Chinese Medicine Research Center from the China Medical University, Taiwan . Funding Information: Dr. Petrides has received research support by the National Institute of Mental Health (NIMH), National Institute of Aging (NIA), and St. Jude Medical . Funding Information: Dr. Kane has been a consultant to Alkermes, Janssen, Pfizer, Bristol-Myers Squibb, Dainippon Sumitomo/Sunovion, Johnson & Johnson, Otsuka, Pierre Fabre, Takeda, IntraCellular Therapies, Merck, Lundbeck, Neurocrine, Reviva, Roche,Teva, and he has received honoraria for lectures from Otsuka, Bristol-Myers Squibb, Janssen and Lundbeck. He is a shareholder LB Pharma and The Vanguard Research Group. He has received grant support from The Center for Medicare and Medicaid Innovation, National Institute of Mental Health , Otsuka , Lundbeck and Janssen .
PY - 2019/9
Y1 - 2019/9
KW - Adherence
KW - Antipsychotics
KW - Long-acting injectable antipsychotics
KW - Perception
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85071391495&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071391495&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2019.07.028
DO - 10.1016/j.schres.2019.07.028
M3 - Letter
C2 - 31371039
AN - SCOPUS:85071391495
VL - 211
SP - 105
EP - 107
JO - Schizophrenia Research
JF - Schizophrenia Research
SN - 0920-9964
ER -